DELAYED UPDATE — ResMed reports FY2026 revenue up 8% and launches $450M ASR
ResMed reported fiscal 2026 revenue of $5.7B, up 8% YoY, citing margin expansion and strong buybacks. It started a $450M accelerated repurchase using cash and MatrixCare sale proceeds and guided to higher fiscal 2027 revenue and EPS.
ResMed Inc. 7B, up 8% year over year, and said margin expansion and strong buybacks supported results. The company also began a $450M accelerated repurchase program using cash and proceeds from the MatrixCare sale, while management guided to higher fiscal 2027 revenue and EPS. KeyBanc raised its price target.